Studies
Scientific References for BPC‑157
Scientific References
At Aloverde, transparency and trust are essential. Re+ (BPC‑157) is not a marketing concept, but the outcome of decades of scientific research. Below, you'll find peer‑reviewed studies examining its wide‑ranging therapeutic potential.
Our aim is to provide reliable, verifiable sources so you can review the evidence directly. Each reference highlights a research area where BPC‑157 has shown promising results.
While science continues to advance, the existing body of evidence helps explain the growing interest among researchers, clinicians, and athletes worldwide.
Explore the references to learn more.
How to Read This Page
- Transparency: We link directly to journals or indexing pages (PubMed/PMC) where possible.
- Scope: Entries emphasize reviews and frequently cited studies for orientation, not exhaustiveness.
- No Claims: Citations do not imply product efficacy or approval for any medical use.
What This Page Includes
- Direct links to peer‑reviewed journals and indexing records.
- Organized research areas (wound/tissue repair, tendons, nerves/CNS, GI & inflammation, regeneration).
- Plain‑language study summaries to help you navigate the literature.
- Selective, high‑signal references—kept concise for easy reading.
1) Acute Injuries & Tissue Repair
- Comprehensive review: Overview of BPC‑157 and wound healing, microvascular effects, and thrombotic counteraction (preclinical focus). Frontiers in Pharmacology, 2021
- GI & soft‑tissue injury (review): Discusses fistula/anastomosis healing and inflammatory modulation; notes limited human data. Pharmaceuticals, 2023 (review)
- Additional background: Earlier mechanistic/overview articles and records: PubMed record, Current Pharmaceutical Design, Molecules, 2014 (overview).
2) Tendons & Connective Tissue
- Tendon fibroblast (in vitro): BPC‑157 increased growth hormone receptor expression in tendon fibroblasts (dose/time dependent). Molecules, 2014
- Connective tissue regeneration (narrative): Collates animal data on tendon/soft‑tissue recovery and microvascular mechanisms. Pharmaceuticals, 2023
3) Nerves & Central Nervous System
- Review: Central nervous system and peripheral nerve models; discusses gut–brain axis hypotheses and calls for rigorous clinical trials. Neural Regeneration Research, 2022
- Related mechanistic/overview items: Neuroscience Letters (abstract), Journal of Applied Physiology.
4) Inflammatory & Gastrointestinal Models
- IBD/ulcer models (review & records): Animal colitis and GI lesion models; notes early clinical exploration and the need for controlled trials. PubMed 18594781, Surg Today, Journal of Surgical Research (abstract).
5) Regeneration & Long‑Term Healing (Preclinical)
- Angiogenesis & microcirculation: Reviews discuss enhanced angiogenesis and endothelial protection as recurring themes in animal studies. See Frontiers in Pharmacology, 2021 and related overviews above.
- Additional bibliography (records & indexes): European Journal of Pharmacology (abstract), Current Medicinal Chemistry (review), CROSBI bibliographic record.
Disclaimers
- FDA statement: These statements have not been evaluated by the Food and Drug Administration. Aloverde products are not intended to diagnose, treat, cure, or prevent any disease.
- Educational content: References are provided for educational transparency only and should not be interpreted as medical advice or a promise of specific outcomes.
- Consult a professional: Speak with a licensed healthcare provider before use, especially if you have a medical condition, take prescription drugs, or are pregnant/nursing. Not for individuals under 18. Keep out of reach of children.
- Individual variability: Responses to any supplement or research compound vary by individual; results are not guaranteed.
- Third‑party links: External links lead to research publishers and indexes that are not affiliated with Aloverde; accuracy and availability may change without notice.
- No endorsement: Inclusion of any publication does not imply endorsement by Aloverde, nor does it indicate regulatory approval.
Regulatory & Compliance Notices (U.S.)
Ingredients and finished products must comply with applicable U.S. laws and regulations. BPC‑157 is not an FDA‑approved active pharmaceutical ingredient. Aloverde does not market any product for the diagnosis, treatment, mitigation, or cure of any disease.
If you are a practitioner or researcher, verify regulatory status and sourcing requirements in your jurisdiction before use.
© Aloverde. All rights reserved. This page is periodically updated for clarity; the latest version controls.